Blue Note Therapeutics will present health economic data to


SAN FRANCISCO, March 24, 2022 (GLOBE NEWSWIRE) — Blue Note Therapeutics today announced that new data from a health economics study on anxiety and depression in Medicare patients living with cancer will be shared at the 2022 National Comprehensive Cancer Network (NCCN) Conference. Data will be shared during the virtual poster session from March 31 to April 2.

The study looked at the additional health costs of anxiety and depression in cancer compared to cancer alone among Medicare beneficiaries. With more than 230,000 patients, the study is the largest and most comprehensive evaluation of its kind.

“As the cancer treatment landscape continues to evolve, at Blue Note we know that an updated understanding of the prevalence and costs of mental health issues in cancer patients has critical implications for cancer care. value-based cancer,” said Michael Malecki, Head of Access and Reimbursement, Blue Note Therapeutics. “Our study finds that one in three Medicare beneficiaries newly diagnosed with cancer suffer from anxiety or depression, leading to a significant increase in healthcare costs. We look forward to sharing the results of our study and the potential solutions at the next NCCN Conference.”

The e-poster and highlights video will be made available to attendees of the NCCN Annual Conference.

E-Poster: Additional Health Care Costs Related to Anxiety and Depression in Medicare Beneficiaries with Cancer

Virtual Poster Session: Thursday March 31 to Saturday April 2

About Cancer Distress

There are approximately 18 million cancer patients and survivors in the United States today.1 Nearly half of all cancer patients suffer from psychosocial distress, anxiety or depression.2 If left untreated, these feelings can reduce a cancer survivor’s quality of life and negatively impact survival.3 The National Comprehensive Cancer Network (NCCN) has established guidelines for providing oncology mental health care services, which include screening patients for signs of distress and implementing a treatment plan to respond these needs with a mental health care specialist.4 Unfortunately, less than half of patients who experience cancer-related distress, which can be defined as an unpleasant sensation, emotion, or experience that affects a patient’s quality of life or ability to cope with diagnosis and cancer treatment, are referred to mental health care. specialists.5.6 Prescription digital therapies designed to address cancer-related distress may help fill this gap in cancer treatment.

About Blue Note Therapeutics

Blue Note Therapeutics is a prescription-only digital therapy company dedicated to serving cancer patients. Our goal is to make treatment accessible to any cancer patient, at any time, by fusing deep scientific and clinical expertise, neuroscience and digital innovation. Working closely with cancer research and patient communities, we are developing a pipeline of clinically validated digital prescription therapies to help reduce anxiety, depression and other forms of cancer-related distress. For more information, visit www.bluenotetherapeutics.com.

About Prescription Digital Therapeutics

Prescription Digital Therapies (PDTs) are a therapeutic class of medical devices that use US Food and Drug Administration (FDA)-approved software to treat diseases and conditions, such as anxiety and depression related to the diagnosis and treatment of cancer. As with prescription drugs, PDTs must demonstrate their safety and effectiveness in randomized clinical trials before they are approved by the FDA.

Media Contact
Kim King
[email protected]
+1 (805) 410-0180

The references

1 American Cancer Society. Cancer facts and figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020. pdf.

2 Mehnert A, Hartung TJ, Friedrich M, et al. One out of two cancer patients is significantly in distress: prevalence and indicators of distress. Psycho-oncology. 2018;27:75-82.

3 Centers for Control and Prevention of Disasters. Use of medications for anxiety and depression in cancer survivors. https://www.cdc.gov/cancer/dcpc/research/articles/anxiety_dep_med_survivors.htm.

4 Comprehensive National Cancer Network. Managing Distress, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. https://jnccn.org/view/journals/jnccn/17/10/article-p1229.xml.

5 OncoLink. What is Cancer Distress? https://www.oncolink.org/support/practical-and-emotional/coping-communication-concerns/what-is-cancer-related-distress.

6 American Cancer Society. Facts and figures about cancer treatment and survivorship 2019-2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship- facts-and-figures-2019-2021.pdf.

Related images

Image 1: Therapeutic Blue Note

This content was posted through the press release distribution service on Newswire.com.

Previous Economic forecast points to calmer real estate market by Ea Ruth
Next Biopharmaceutical Contract Manufacturing Market Entry Strategies, Economic Impact Channel Countermeasures to 2028 | Lonza Group Ltd., ProBioGen AG, Boehringher Ingelheim, BIOMEVA GmbH,